Ketone body therapy: From the ketogenic diet to the oral administration of ketone ester

Journal of Lipid Research

Volumn 55, Issue 9, 2014, Pages 1818-1826

  Hashim, Sami A ^a   VanItallie, Theodore B ^a  

^a Department of Medicine St Luke'S Roosevelt Hospital Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

1,3 butanediol monoester of hydroxybutyrate; Alzheimer's disease; Epilepsy; Glyceryl tris 3 hydroxybutyrate; Histone acetylation; Hyperketonemia; Ketoacidosis; Mitochondrial dysfunction; Parkinson's disease

Indexed keywords

ESTER; KETONE BODY;

ANIMAL; BRAIN; DIET THERAPY; ENERGY METABOLISM; EPILEPSY; HUMAN; KETOGENIC DIET; METABOLISM; PARKINSON DISEASE; PHYSIOLOGY;

ANIMALS; BRAIN; ENERGY METABOLISM; EPILEPSY; ESTERS; HUMANS; KETOGENIC DIET; KETONE BODIES; PARKINSON DISEASE;

EID: 84904752002     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R046599     Document Type: Review

References (89)

1. VanItallie, T. B., and T. H. Nufert. 2003. Ketones: metabolism's ugly duckling. Nutr. Rev. 61: 327-341. (Pubitemid 37243711)
2. Owen, O. E., A. P. Morgan, H. G. Kemp, J. M. Sullivan, M. G. Herrera, and G. F. Cahill, Jr. 1967. Brain metabolism during fasting. J. Clin. Invest. 46: 1589-1595.
3. Cahill, G. F., Jr. 2006. Fuel metabolism in starvation. Annu. Rev. Nutr. 26: 1-22.
4. Cahill, G. F., Jr. 1983. President's address: starvation. Trans. Am. Clin. Climatol. Assoc. 94: 1-21.
5. Cahill, G. F., and R. L. Veech. 2003. Ketoacids? Good medicine. Trans. Am. Clin. Climatol. Assoc. 114: 149-163.
6. Auestad, N., R. A. Korsak, J. W. Morrow, and J. Edward. 1991. Fatty acid oxidation and ketogenesis by astrocytes in primary culture. J. Neurochem. 56: 1376-1386. (Pubitemid 21902060)
7. Bixel, M. G., and B. Hamprecht. 1995. Generation of ketone bodies from leucine by cultured astroglial cells. J. Neurochem. 65: 2450-2461.
8. Guzmán, M., and C. Blázquez. 2004. Ketone bodies synthesis in the brain: possible neuroprotective effects. Prostaglandins Leukot. Essent. Fatty Acids. 70: 287-292.
9. Morris, A. A. 2005. Cerebral ketone metabolism. J. Inherit. Metab. Dis. 28: 109-121.
10. Bentourkia, M., S. Tremblay, F. Pifferi, J. Rousseau, R. Leomte, and S. Cunnane. 2009. PET study of 11C-acetoacetate kinetics in rat brain during dietary treatments affecting ketosis. Am. J. Physiol. Endocrinol. Metab. 296: E796-E801.
11. Ruderman, N. B., P. S. Ross, M. Berger, and M. N. Goodman. 1974. Regulation of glucose and ketone-body metabolism in brain of anaesthetized rats. Biochem. J. 138: 1-10.
12. Laffel, L. 1999. Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab. Res. Rev. 15: 412-426. (Pubitemid 30066228)
13. Schon, E. A., and G. Manfredi. 2003. Neuronal degeneration and mitochondrial dysfunction. J. Clin. Invest. 111: 303-312. (Pubitemid 36182203)
14. Veech, R. L. 2004. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redux states insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot. Essent. Fatty Acids. 70: 309-319. (Pubitemid 38200957)
15. Costantini, L. C., L. J. Barr, J. I. Vogel, and S. T. Henderson. 2008. Hypometabolism as a therapeutic target in Alzheimer's disease. BMC Neurosci. 9 (Suppl. 2): S16.
16. Talbot, K., H-Y. Wang, H. Kazi, L-Y. Ham, K. P. Bakshi, A. Stucky, R. L. Fuino, K. R. Kawaguchi, A. J. Samoyedny, R. S. Wilson, et al. 2012. Demonstrated brain insulin resistance in Alzheimer's disease is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 122: 1316-1338.
17. Laeger, T., C. C. Metges, and B. Kuhla. 2010. Role of β-hydroxybutyrate in the central regulation of energy balance. Appetite. 54: 450-455.
18. Madison, L. L., D. Mebane, R. H. Unger, A. Lochner. 1964. The hypoglycemic action of ketones II. Evidence for a stimulatory feedback of ketones on the pancreatic beta cells. J. Clin. Invest. 43: 408-415.
19. Pi-Sunyer, F. X., R. G. Campbell, and S. A. Hashim. 1970. Experimentally induced hyperketonemia and insulin secretion in the dog. Metabolism. 19: 263-270.
20. Cahill, G. F. Jr., M. G. Herrera, A. P. Morgan, J. S. Soeldner, J. Steinke, P. L. Levy, G. A. Reichard, and D. M. Kipnis. 1966. Hormone-fuel interrelationships during fasting. J. Clin. Invest. 45: 1751-1768.
21. Garber A. J., P. H. Menzel, G. Boden, and O. E. Owen. 1974. Hepatic ketogenesis and gluconeogenesis in humans. J. Clin. Invest. 54: 981-989.
22. Veech, R. L., B. Chance, Y. Kashiwaya, H. A. Lardy, and G. F. Cahill Jr. 2001. Ketone bodies, potential therapeutic uses. IUBMB Life. 51: 241-247. (Pubitemid 32848155)
23. Cotter, D. G., R. C. Schugar, and P. A. Crawford, 2012. Ketone body metabolism and cardiovascular diseases. Am J Physiol. ePub ahead of print. DOI:10.1152/ajpheart.00646.2012.
24. Kashiwaya, Y., K. Sato, N. Tsuchiya, S. Thomas, D. A. Fell, R. L. Veech, and J. V. Passonneau. 1994. Control of glucose utilization in working perfused rat heart. J. Biol. Chem. 269: 25502-25514. (Pubitemid 24336239)
25. Sato, K., Y. Kashiwaya, C. A. Keon, N. Tsuchiya, M. T. King, G. K. Radda, B. Chance, K. Clarke, and R. L. Veech. 1995. Insulin, ketone bodies, and mitochondrial energy metabolism. FASEB J. 9: 651-658.
26. Burne, J. 2012. Could this elixir hold the key to weight loss? Experts hope it'll also treat diabetes, epilepsy and Alzheimer's. http://www.dailymail. co.uk/health/article-2238842/
27. Boumezbeur, F., G. F. Mason, R. A. de Graaf, K. L. Behar, G. W. Cline, G. I. Shulman, D. L. Rothman, and K. F. Petersen. 2010. Altered brain mitochondrial metabolism in healthy ageing as assessed by in vivo magnetic resonance spectroscopy. J. Cereb. Blood Flow Metab. 30: 211-221.
28. Silva, D. F. F., A. R. Esteves, C. R. Oliveira, and S. M. Cardoso. 2011. Mitochondria: the common upstream driver of amyloid-β and tau pathology in Alzheimer's disease. Curr Alzheimer Res. 8: 563-572.
29. VanItallie, T. B. 2013. Preclinical sporadic Alzheimer's disease: target for personalized diagnosis and preventive intervention. Metabolism. 62 (Suppl. 1): S30-S33.
30. Chou, J. L., D. V. Shenoy, N. Thomas, P. K. Choudhary, F. M. La Ferla, S. R. Goodman, and G. A. M. Breen. 2011. Early dysregulation of the mitochondrial proteome in a mouse model of Alzheimer's disease. J. Proteomics. 74: 466-479.
31. Hoyer, S. 1991. Abnormalities of glucose metabolism in Alzheimer's disease. Ann. N. Y. Acad. Sci. 640: 53-58.
32. Ishii, K., M. Sasaki, H. Kitagaki, S. Yamaji, S. Sakamoto, K. Matsuda, and E. Mori. 1997. Reduction of cerebral glucose metabolism in advanced Alzheimer's disease. J. Nucl. Med. 38: 925-928. (Pubitemid 27251986)
33. Blass, J. P. 2000. The mitochondrial spiral. An adequate cause of dementia in Alzheimer's syndrome. Ann. N. Y. Acad. Sci. 924: 170-183. (Pubitemid 32050199)
34. Hoyer, S. 2004. Causes and consequences of disturbance of glucose metabolism in sporadic Alzheimer's disease: therapeutic implications. Adv. Exp. Med. Biol. 541: 135-152. (Pubitemid 38037371)
35. Reddy, P. H., and M. F. Beal. 2008. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol. Med. 14: 45-53.
36. Crouch, P. J., S-M. E. Harding, A. R. White, J. Camakaris, A. I. Bush, and C. L. Masters. 2008. Mechanism of Aβ mediated neurodegeneration in Alzheimer's disease. Int. J. Biochem. Cell Biol. 40: 181-198. (Pubitemid 350137874)
37. Moreira, P. I., A. I. Duarte, M. S. Santos, A. C. Rego, and C. R. Olivera. 2009. An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer's disease. J. Alzheimers Dis. 16: 741-761.
38. Mosconi, L., R. Mistur, R. Switalski, W. H. Tsui, L. Glodzik, Y. Li, E. Pirraglia, S. De Santi, B. Reisberg, T. Wisniewski, et al. 2009. FDGPET changes in brain glucose metabolism from normal to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol. Imaging. 36: 811-822.
39. Simpson, I. A., K. R. Chundu, T. Davies-Hill, W. G. Honer, and P. Davies. 1994. Decreased concentrations of GLUT 1 and GLUT 3 in brains of patients with Alzheimer's disease. Ann. Neurol. 35: 546-551. (Pubitemid 24153837)
40. Liu, Y., F. Liu, K. Iqbal, I. Grundke-Iqbal, and C. X. Gong. 2008. Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer's disease. FEBS Lett. 582: 359-364.
41. Cunnane, S., S. Nugent, M. Roy, A. Courchesne-Loyer, E. Croteau, S. Tremblay, A. Castellano, F. Pifferi, C. Bocti, N. Paquet, et al. 2011. Brain fuel metabolism, aging, and Alzheimer's disease. Nutrition. 27: 3-20.
42. Castellano, C. A., S. Nugent, S. Tremblay, M. Fortier, N. Pacquet, C. Bocti, M. Lepage, E. Turcotte, T. Fulop, and S. C. Cunnane. 2013. In contrast to lower glucose uptake, brain ketone uptake is unchanged in mild Alzheimer's disease. A dual tracer study comparing 18FDG and 11C-acetoacetate (Abstract). J. Nutr. Health Aging. 17: 810-811.
43. Shestov, A. A., U. E. Emir, A. Kumar, P.-G. Henry, E. R. Seaquist, and G. Oz. 2011. Simultaneous measurement of glucose transport and utilization in the human brain. Am. J. Physiol. Endocrinol. Metab. 301: E1040-E1049.
44. Kashiwaya, Y., C. Bergman, J. H. Lee, R. Wan, M. T. King, M. R. Mughal, E. Okun, K. Clarke, M. P. Mattson, and R. L. Veech. 2013. A ketone ester diet exhibits anxiolytic and cognition properties and lessens amyloid and tau pathologies in a mouse model of Alzheimer's disease. Neurobiol. Aging. 34: 1530-1539.
45. Peleg, S., F. Sananbenesi, A. Zovoilis, S. Bukhardt, S. Bahari-Javan, R. C. Agis-Balboa, P. Cota, J. L. Wittnam, A. Gogol-Doering, L. Opitz, et al. 2010. Altered histone acetylation is associated with age-ependent memory impairment in mice. Science. 328: 753-756.
46. Agis-Balboa, R. C., Z. Pavelka, C. Kerimoglu, and A. Fischer. 2013. Loss of HDAC 5 impairs memory function: implications for Alzheimer's disease. J. Alzheimers Dis. 33: 35-44.
47. Shimazu, T., M. D. Hirschey, J. Newman, W. He, K. Shirakawa, N. L. Moan, C. A. Grueter, H. Lim, L. R. Saunders, R. D. Stevens, et al. 2013. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 339: 211-214.
48. Blesa J., V. Jackson-Lewis, N. Boaz, S. Hashim, and S. Przedborski. 2012 Glyceryl-tris-3-hydroxybutyrate protects dopaminergic neurons in a MPTP model of Parkinson's disease (Abstract in 2012 Neuroscience Meeting Planner, Society for Neuroscience. New Orleans, LA, October 17, 2012).
49. Kilgore, M., C. A. Miller, D. M. Fass, K. M. Hennig, S. J. Haggarty, J. D. Sweatt, and G. Rumbaugh. 2010. Inhibitors of class I histone deacetylase reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology. 35: 870-880.
50. VanItallie, T. B. 2008. Parkinson disease: primacy of age as a risk factor for mitochondrial dysfunction. Metabolism. 57 (Suppl. 2): S50-S55.
51. Büeler, H. 2009. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. Exp. Neurol. 218: 235-246.
52. Langston, J. W., J. W. Tetrud, and I. Irwin. 1983. Chronic Parkinsonism in humans due to a product of meperidine-analogue synthesis. Science. 219: 979-980. (Pubitemid 13189531)
53. Nicklas, W. J., S. K. Youngster, M. V. Kindt, and R. E. Heikkila. 1987. MPTP, MPP+ and mitochondrial function. Life Sci. 40: 721-729.
54. Greenamyre, J. T., T. B. Sherer, R. Betarbet, and A. V. Pavov. 2001. Complex I and Parkinson's disease. IUBMB Life. 52: 135-141. (Pubitemid 33731566)
55. Tieu, K., C. Perier, C. Casperson, P. Teismann, D. C. Wu, S. D. Yan, A. Naini, M. Vila, V. Jackson-Lewis, R. Ramasamy, et al. 2003. D- betahydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson's disease. J. Clin. Invest. 112: 892-901. (Pubitemid 38063747)
56. Kashiwaya, Y., T. Takeshima, N. Mori, K. Nakashima, K. Clarke, and R. L. Veech. 2000. D-beta-hydroxybutyrate protects neurons of Alzheimer's and Parkinson's disease. Proc. Natl. Acad. Sci. USA. 97: 5440-5444. (Pubitemid 30313737)
57. Cheng, B., X. Yang, A. Liangxiang, B. Gao, X. Liu, and S. Liu. 2009. Ketogenic diet protects dopaminergic neurons against 6-OHDA neurotoxicity via up-regulating glutathione in a rat model of Parkinson's disease. Brain Res. 1286: 25-31.
58. Kim, D. Y., L. M. Davis, P. G. Sullivan, M. Maalouf, T. A. Simeone, J. van Breolerode, and J. M. Rho. 2007. Ketone bodies are protective against oxidative stress in neocortical neurons. J. Neurochem. 101: 1316-1326. (Pubitemid 46718821)
59. Kim, D. Y., J. Vellejo, and J. M. Rho. 2010. Ketones prevent synaptic dysfunction induced by respiratory complex inhibitors. J. Neurochem. 114: 130-141.
60. Wilder, R. M. 1921. The effects of ketonemia on the course of epilepsy. Mayo Clin Bull. 2: 307-308.
61. Fuehrlein, B. S., and M. S. Rutenberg, J. N. Silver, M. W. Warren, D. W. Theriaque, G. E. Duncan, P. W. Stacpoole, and M. L. Brantly. 2004. Differential metabolic effects of saturated versus polyunsaturated fats in ketogenic diets. J. Clin. Endocrinol. Metab. 89: 1641-1645. (Pubitemid 38507914)
62. Huttenlocher, P. R., A. J. Wilbourn, and J. M. Signore. 1971. Medium chain triglyceride as a therapy for intractable childhood epilepsy. Neurology. 21: 1097-1103.
63. Wu, P. Y. K., J. Edmond, N. Avestad, S. Rambathla, J. Benson, and T. Picone. 1986. Medium chain triglycerides In infant formulas and their relation to plasma ketone body concentration. Pediatr. Res. 20: 338-341. (Pubitemid 16104444)
64. Balietti, M., T. Gasoli, G. DiStefano, B. Giorgetti, G. Aicardi, and P. Pattovetti. 2010. Ketogenic diets: an historical antiepileptic therapy with promising potentialities for the aging brain. Ageing Res. Rev. 9: 273-279.
65. Neal, E. G., H. Chaffe, R. H. Schwartz, M. S. Lawson, N. Edwards, G. Fitzsimmons, A. Whitney, and J. H. Cross. 2009. A randomized trial of classical and medium-chain triglyceride ketogenic diets in the treatment of epilepsy. Epilepsia. 50: 1109-1117.
66. Hong, A. M., Z. Turner, R. F. Hamdy, and E. H. Kossoff. 2010. Infantile spasms treated with the ketogenic diet: prospective single-center experience in 104 consecutive infants. Epilepsia. 51: 1403-1407.
67. Numis, A. L., M. B. Yellen, C. J. Chu-Shore, H. Pfeifer, and E. A. Theile. 2011. The relationship of ketosis and growth to the efficacy of the ketogenic diet in infantile spasm. Epilepsy Res. 96: 172-175.
68. Yudkoff, M., Y. Daikhin, O. Horyn, I. Nissim, and I. Nissim. 2008. Ketosis and brain handling of glutamate, glutamine, and GABA. Epilepsia. 49 (Suppl. 8): 73-75.
69. Freeman, J. M., E. P. Viking, D. L. Pillas, P. L. Pyzik, J. C. Casey, and L. M. Kelly. 1998. The efficiency of the ketogenic diet-1998: a prospective evaluation of intervention in 150 children. Pediatrics. 102: 1358-1363. (Pubitemid 28550826)
70. Likhodii, S. S., K. Musa, A. Meneonca, C. Dell, W. M. Burnham, and S. C. Cunnane. 2000. Dietary fat, ketosis, and seizure resistance in rats on ketogenic diet. Epilepsia. 41: 1400-1410.
71. Rho, J. M., G. D. Anderson, S. D. Donevan, and H. S. White. 2002. Acetoacetate, acetone, and dibenzylamine (a contaminant in L-(+)- betahydroxybutyrate) exhibit direct anticonvulsant actions in vivo. Epilepsia. 43: 358-361. (Pubitemid 34297173)
72. Stafstrom, C. E., and K. J. Bough. 2003. The ketogenic diet for the treatment of epilepsy: a challenge for nutritional neuroscientists. Nutr. Neurosci. 6: 67-79. (Pubitemid 36417038)
73. Likhodii, S., K. Nylen, and W. M. Burnham. 2008. Acetone as an anticonvulsant. Epilepsia. 49 (Suppl. 8): 83-86.
74. Nei, M., L. Ngo, J. I. Sirven, and M. R. Sperling. 2014. Ketogenic diet in adolescents and adults with epilepsy. Seizure. 23: 439-442.
75. Kossoff, E. H., B. A. Zupec-Kania, and J. M. Rho. 2009. Ketogenic diets: an update for child neurologists. J. Child Neurol. 24: 979-988.
76. McNally, M. A., and A. L. Hartman. 2012. Ketone bodies in epilepsy. J. Neurochem. 121: 28-35.
77. Kashiwaya, Y., R. Pawlosky, W. Markis, M. T. King, C. Bergman, S. Srivastava, A. Murray, K. Clarke, and R. L. Veech. 2010. A ketone ester diet increased brain malony-CoA and uncoupling protein 4 and 5 while decreasing food intake in the normal Wistar rat. J. Biol. Chem. 285: 25950-25956.
78. D'Agostino, D. P., R. Pilla, H. F. Held, C. S. Landon, M. Puchowicz, H. Brunengraber, C. Ari, P. Arnold, and J. B. Dean. 2013. Therapeutic ketosis with ketone ester delays central nervous system oxygen toxicity seizures in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 304: R829-R836.
79. Clarke, K., K. Tchabanenko, R. Pawlosky, E. Carter, M. T. King, K. Musa-Veloso, M. Ho, A. Roberts, J. Robertson, T. B. VanItallie, et al. 2012. Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. Regul. Toxicol. Pharmacol. 63: 401-408.
80. Clarke, K., K. Tchabamenko, R. Pawlosky, E. Carter, N. S. Knight, A. J. Murray, L. E. Cochlin, M. T. King, A. W. Wong, A. Roberts, et al. 2012. Oral 28-day and developmental toxicity studies of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate. Regul. Toxicol. Pharmacol. 63: 196-208.
81. Desrochers, S., K. Quinze, H. Dugas, P. Debreuil, C. Bomont, F. David, K. C. Agarwal, A. Kumar, M. V. Soloviev, L. Powers, et al. 1995. R,S-1,3-butanediol acetoacetate esters, potential alternates to lipid emulsions for parenteral nutrition. J. Nutr. Biochem. 6: 111-118.
82. Desrochers, S., P. Dubreuil, J. Brunet, M. Jetté, F. David, B. R. Landau, and H. Brunengraber. 1995. Metabolism of (R,S)-1,3-butanediol acetoacetate esters, potential parenteral and enteral nutrients in conscious pigs. Am J Physiol. 268: E660-E667.
83. Srivastava, S., Y. Kashiwaya, M. T. King, U. Baxa, J. Tam, G. Niu, X. Chen, K. Clarke, and R. L. Veech. 2012. Mitochondrial biogenesis and increased uncoupling protein 1 in brown adipose tissue of mice fed a ketone ester diet. FASEB J. 26: 2351-2362.
84. Srivastava, S., Y. Kashiwaya, M. T. King, U. Baxa, J. Tam, G. Niu, X. Chen, K. Clarke, and R. L. Veech. 2012. Mitochondrial biogenesis and increased uncoupling protein 1 in brown adipose tissue of mice fed a ketone ester diet. FASEB J. 26: 2351-2362.
85. Birkhahn, R. H., C. McCombs, R. Clemens, and J. Hubbs. 1997. Potential of the monoglyceride and triglyceride of DL-3-hydroxybutyrate for parenteral nutrition: synthesis and preliminary biological testing in the rat. Nutrition. 13: 213-219. (Pubitemid 27184890)
86. Brunengraber, H. 1997. Potential of ketone body esters for parenteral nutrition. Nutrition. 13: 233-235. (Pubitemid 27184896)
87. Scala, R. A., and O. E. Paynter. 1967. Chronic oral toxicity of 1,3-butanediol. Toxicol. Appl. Pharmacol. 10: 160-164.
88. Tobin, R. B., L. H. Garthoff, M. A. Mehlman, and R. L. Veech. 1978. Metabolite levels, redox states, and gluconeogenic enzyme activities in livers of rats fed diets containing 1,3-butanediol. J Environ Pathol Toxicol. 2: 389-398. (Pubitemid 9246956)
89. Romsos, D. R., P. S. Belo, and G. A. Leveille. 1975. Butanediol and lipid metabolism. Fed. Proc. 34: 2186-2190.